Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50626
Name gastrointestinal neuroendocrine tumor
Definition A gastrointestinal system cancer that has_material_basis_in neuroendocrine cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer gastrointestinal neuroendocrine tumor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Pazopanib gastrointestinal neuroendocrine tumor not applicable detail...
Unknown unknown Lanreotide acetate gastrointestinal neuroendocrine tumor not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02250885 Phase II Selinexor KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed USA 0
NCT02315625 Phase II Everolimus Sunitinib Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery Terminated USA 0
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting USA 0
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Active, not recruiting USA 1
NCT02955069 Phase II Spartalizumab Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Completed USA | CAN 11
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting USA 0
NCT03043664 Phase Ib/II Lanreotide acetate + Pembrolizumab Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET) Active, not recruiting USA 0
NCT03049189 Phase III 177Lu-edotreotide Everolimus Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Recruiting USA 12
NCT03278379 Phase II Avelumab Avelumab in G2-3 NET (NET-002) Active, not recruiting CAN 0
NCT03278405 Phase Ib/II Avelumab Avelumab in G3 NEC (NET-001) Completed CAN 0
NCT03411915 Phase I XmAb18087 A Study of XmAb18087 in Subjects With NET and GIST Recruiting USA 0
NCT03420521 Phase II Ipilimumab + Nivolumab Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Active, not recruiting USA 0
NCT03670030 Phase II Nab-Rapamycin A Study to Test the Effectiveness of ABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System Active, not recruiting USA 0
NCT03879694 Phase I Octreotide + Sargramostim + SurVaxM Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors Recruiting USA 0
NCT03891784 Phase II Abemaciclib Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors Recruiting USA 0
NCT03901378 Phase II Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma Withdrawn USA 0
NCT03972488 Phase III Octreotide acetate lutetium Lu 177 dotatate + Octreotide acetate Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) Recruiting USA | CAN 6
NCT04086485 Phase Ib/II lutetium Lu 177 dotatate + Olaparib Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) Not yet recruiting USA 0
NCT04123262 Phase II Tamoxifen Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression Recruiting USA 0
NCT04609592 Phase I lutetium Lu 177 dotatate Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery Not yet recruiting USA 0